E M H Swiss Medical Publishers Ltd

SHERPA: Unknown

People

  1. Rosenberg
    Rosenberg
  2. Morris
    Morris

Groups

  1. Department of Medicine (5)
  2. Genitourinary Oncology Service (5)
  3. Solid Tumor Oncology Division (5)
Search Within
  1. "Genitourinary Oncology Service"
Formats
  1. Meeting Abstract (5)
Groups
  1. Department of Medicine (5)
  2. Genitourinary Oncology Service (5)
  3. Solid Tumor Oncology Division (5)
People
  1. Jonathan Rosenberg (3)
  2. Michael Morris (2)
Years
  1. 2022 (3)
  2. 2021 (1)
  3. 2020 (1)
Publications
  1. Swiss Medical Weekly (5)

Results (5)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • PSMAfore: A phase 3 study comparing 177Lu-PSMA-617 treatment with change in androgen receptor pathway inhibitor in taxane-naïve patients with mCRPC
    Meeting Abstract

    Lorch, A.; Berthold, D.; Burger, I.; Morris, M.; Sartor, O.; Chi, K.; de Bono, J.; Shore, N.; Crosby, M.; Dalal, D.; more...
    Swiss Medical Weekly (2022)

    Fulltext@MSK | Save
  • PSMAddition: A phase 3 trial to compare treatment with 177Lu-PSMA-617 plus SOC versus SOC alone in patients with metastatic HSPC
    Meeting Abstract

    Berthold, D.; Tagawa, S.; Sartor, O.; Parker, C.; Saad, F.; Sakharova, O.; de Bono, J.; Feng, F.; Fizazi, K.; Morris, M.
    Swiss Medical Weekly (2022)

    Fulltext@MSK | Save
  • EV-301 long-term outcomes: 24-month findings from phase 3 trial of enfortumab vedotin vs chemotherapy in previously treated advanced urothelial carcinoma
    Meeting Abstract

    Rosenberg, J.; Powles, T.; Sonpavde, G.; Loriot, Y.; Duran, I.; Lee, J.; Matsubara, N.; Vulsteke, C.; Castellano, D.; Mamtani, R.; more...
    Swiss Medical Weekly (2022)

    Fulltext@MSK | Save
  • Quality of life, functioning, and symptoms in patients with previously treated locally advanced or metastatic urothelial carcinoma from EV-301
    Meeting Abstract

    Gurney, H.; Mamtani, R.; Rosenberg, J. E.; Powles, T.; Sonpavde, G. P.; Loriot, Y.; Duran, I.; Lee, J. L.; Matsubara, N.; Vulsteke, C.; more...
    Swiss Medical Weekly (2021)

    Fulltext@MSK | Save
  • First-line (1L) enfortumab vedotin plus pembrolizumab demonstrates durable antitumour activity in cisplatin-ineligible patients with locally advanced/metastatic urothelial carcinoma (la/mUC)
    Meeting Abstract

    Rosenberg, J. E.; Flaig, T. W.; Friedlander, T. W.; Milowsky, M. I.; Srinivas, S.; Petrylak, D. P.; Merchan, J. R.; Bilen, M. A.; Carret, A. S.; Yuan, N.; more...
    Swiss Medical Weekly (2020)

    Fulltext@MSK | Save

    • E M H Swiss Medical Publishers Ltd – authorized name for: